Press releases

03 Aug 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

28 Apr 2015

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

Press contact

Sebastiaan van den Bovenkamp, Communications specialist
T +31(0)6 205 702 88
E communications@synthon.com